Is colistin safe to take?

Colistin carries real toxicity risks—particularly nephrotoxicity (kidney damage) occurring in 15–50% of patients—but these are manageable with careful monitoring, appropriate dosing, and short treatment durations. It's only used when the infection is serious and other antibiotics have failed, because the benefit of treating a life-threatening MDR infection typically outweighs the risks.

How is colistin different from other antibiotics?

Colistin disrupts bacterial cell membranes directly, a mechanism that works against most gram-negative bacteria even when they're resistant to other antibiotics. However, unlike newer antibiotics, it has significant toxicity and must be dosed carefully. It's reserved for truly difficult infections, not routine use.

Can bacteria become resistant to colistin?

Yes. Colistin-resistant bacteria exist and are emerging, particularly in Asia and Europe. This is why colistin is designated a reserve agent—overuse would accelerate resistance and eliminate one of our last-resort options. It should only be used when culture data confirms the organism is susceptible and no alternatives exist.

What infections is colistin used to treat?

Colistin treats serious infections caused by multidrug-resistant gram-negative bacteria, particularly hospital-acquired pneumonia (VAP), bloodstream infections, and urinary tract infections when susceptible. It's also used as inhaled therapy for cystic fibrosis patients. It's never a first-choice antibiotic.

How many clinical trials has colistin been studied in?

Colistin has been evaluated in 119 documented clinical trials, covering efficacy, safety, optimal dosing, and combination therapy approaches. This substantial research base has guided modern clinical protocols and dosing strategies that balance effectiveness against toxicity risks.

Colistin Complete Guide: Everything You Need to Know

Colistin is an FDA-approved antibiotic that belongs to a class called polymyxins, originally discovered in the 1940s but largely abandoned for decades due to toxicity concerns. In recent years, it has made a dramatic comeback as a critical treatment for multidrug-resistant (MDR) bacterial infections—particularly those caused by organisms like Pseudomonas aeruginosa and Acinetobacter baumannii that resist nearly all other antibiotics. With 119 clinical trials on record, colistin represents a fascinating case study in how old drugs are being revived to combat the growing threat of antibiotic resistance. This guide walks you through everything: how it works at the molecular level, what the clinical evidence shows, its safety profile, regulatory approvals across major markets, and what makes it such a critical tool in modern infectious disease medicine.

What Is Colistin?

Colistin is a cyclic polypeptide antibiotic—essentially a chain of amino acids—that was first isolated from the bacterium Bacillus polymyxa in 1947. For most of its history, it was considered too toxic for systemic (bloodstream) use, so it was relegated to topical applications and inhaled delivery. But as bacterial resistance to modern antibiotics has accelerated, colistin has been dusted off and repositioned as a last-resort agent for infections that nothing else can touch.

Today, colistin is approved by the FDA, EMA, and Health Canada for treating serious infections caused by MDR gram-negative bacteria. It's a true reserve weapon—doctors don't reach for it as a first choice, but when they need it, there's often no alternative.

How Colistin Works: The Mechanism

Colistin's mechanism is elegant and brutal. It targets the outer membrane of gram-negative bacteria—a lipid bilayer that's fundamentally different from the cell walls of gram-positive bacteria or human cells.

Here's what happens:

Membrane disruption: Colistin binds to lipopolysaccharide (LPS), a major component of the gram-negative bacterial outer membrane. This interaction causes the membrane to destabilize and lose integrity.
Ion leakage: Once the membrane is compromised, essential ions and nutrients leak out of the bacterial cell.
Cell death: The bacterium dies because it can no longer maintain its internal environment.

This mechanism is why colistin is so effective against gram-negative bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii—but also why it can be hard on human tissues, since mammalian cells also contain membranes (though colistin preferentially targets bacterial membranes).

Clinical Evidence and Research

With 119 documented clinical trials, the research base for colistin is substantial. Here's what the evidence shows:

Efficacy in MDR Infections

Studies demonstrate that colistin remains active against the vast majority of MDR gram-negative bacteria, including strains resistant to carbapenems (one of the most powerful antibiotic classes). In hospital settings, particularly intensive care units (ICUs), colistin has been shown to reduce mortality in patients with severe sepsis caused by highly resistant organisms.

For example, in critically ill patients with Acinetobacter baumannii infections—organisms often dubbed "Acinetobacter baumannii"—colistin monotherapy or combination therapy has shown survival benefits when compared to standard agents. The key finding: colistin often remains the only active option.

Combination Therapy Advantage

Recent evidence suggests that combining colistin with other antibiotics (like rifampicin or carbapenems at higher doses) may improve outcomes compared to colistin alone. This has shifted clinical practice toward combination regimens in some institutions, particularly for serious infections like ventilator-associated pneumonia (VAP) and bloodstream infections.

Pharmacokinetics

Colistin's behavior in the body is complex. It exists in two forms: colistin (the inactive prodrug) and colistimethate sodium (the active metabolite). The drug distributes widely into body tissues, including lung and kidney, but achieves lower concentrations in the central nervous system—a limitation for treating meningitis. This is why dosing strategies have evolved; higher doses are now used in severe infections compared to older protocols.

Regulatory Status

Colistin holds major regulatory approvals:

FDA: Approved for systemic use; available as Coly-Mycin M parenteral formulation.
EMA: Authorized for treating serious infections caused by sensitive gram-negative organisms.
Health Canada: Approved for similar indications as the FDA and EMA.

These approvals are based on decades of clinical use data, though approval predates modern clinical trial standards. The regulatory agencies have supported colistin's re-emergence because the clinical need is acute and alternatives are genuinely limited.

Safety Profile and Tolerability

Colistin's return to prominence came with a critical caveat: managing its toxicity profile.

Nephrotoxicity (Kidney Damage)

The most significant concern is nephrotoxicity—damage to the kidneys. Incidence rates of colistin-associated acute kidney injury (AKI) range from 15–50% depending on the patient population and dosing strategy. Most cases are reversible if the drug is discontinued, but in critically ill patients with pre-existing renal impairment, this is a serious risk.

Modern dosing protocols emphasize:

Loading doses to achieve rapid therapeutic levels
Maintenance dosing adjusted for renal function
Careful monitoring of serum creatinine and urine output

Neurotoxicity

Colistin can cause neuromuscular blockade and neurotoxicity, including tingling, dizziness, and rarely, respiratory paralysis. These effects are dose-dependent and usually reversible. Incidence is lower with current dosing strategies than with historical protocols.

Other Adverse Effects

Respiratory distress: Particularly in patients receiving mechanical ventilation (colistin-induced apnea is rare but reported).
Gastrointestinal symptoms: Nausea, diarrhea (less common with parenteral dosing).
Allergic reactions: Uncommon but possible.

Managing Risk

The key to safe colistin use is aggressive monitoring:

Baseline and regular renal function tests
Neurological assessment if patients report symptoms
Dose optimization using therapeutic drug monitoring (TDM) where available
Shortest duration of therapy consistent with clinical response

Resistance and Emerging Concerns

As colistin use has increased globally, reports of colistin-resistant gram-negative bacteria have surfaced, particularly in Asia and Europe. The most notable is the mcr-1 gene, which confers colistin resistance and can spread between bacteria.

This is a serious long-term concern: if widespread colistin resistance emerges, one of the last-resort antibiotics will be lost. This underscores why colistin should be used judiciously—only when truly indicated—and why stewardship programs emphasize its reserve status.

Comparison with Related Compounds

Colistin sits within the polymyxin class. Polymyxin B is a closely related compound with a similar mechanism and comparable toxicity profile. In some regions, polymyxin B is preferred; in others, colistin is standard. Both are reserved for MDR gram-negative infections.

Other last-resort agents for gram-negative bacteria include ceftazidime-avibactam (a newer beta-lactam–beta-lactamase inhibitor combination) and meropenem-vaborbactam, which are often preferred as first-line alternatives to colistin when available, due to potentially better tolerability profiles.

Clinical Trial Landscape

The 119 clinical trials on colistin span multiple phases and indications:

Efficacy and safety: Comparative studies against other agents or placebo in MDR infections.
Dosing optimization: Studies to refine loading and maintenance dosing strategies to maximize efficacy while minimizing nephrotoxicity.
Combination therapy: Trials investigating colistin combined with other antibiotics for synergistic effects.
Specific populations: Studies in cystic fibrosis patients (who receive inhaled colistin), burn patients, and ICU cohorts.

These trials have significantly improved our understanding of how to use colistin safely and effectively.

Current Clinical Use and Indications

Today, colistin is indicated for:

Serious infections caused by MDR gram-negative bacteria when susceptible organisms are confirmed on culture.
Ventilator-associated pneumonia (VAP) caused by resistant Pseudomonas or Acinetobacter.
Bloodstream infections (bacteremia/sepsis) from resistant gram-negatives.
Urinary tract infections (UTIs) from resistant organisms, though other options are usually preferred.
Cystic fibrosis lung infections: Inhaled colistin is standard for managing Pseudomonas colonization.

Colistin is NOT appropriate for routine infections or as first-line therapy—the nephrotoxicity risk and resistance concerns make it a true reserve agent.

The Future: Colistin Alternatives

Research into novel antimicrobials is ongoing. New beta-lactam–inhibitor combinations, fluoroquinolones, and even unconventional approaches (like phage therapy) are in development. The hope is that colistin's role will eventually narrow again as better, safer alternatives emerge.

However, for now, colistin remains an irreplaceable tool. Its revival is bittersweet: essential because antibiotic resistance is so severe, but limited by toxicity and the ever-present risk of resistance development.

Key Takeaways

Colistin is an old antibiotic with new importance in the era of MDR bacteria.
It works by disrupting bacterial cell membranes, making it highly effective against gram-negatives.
Clinical evidence from 119 trials supports its use in serious infections when alternatives are unavailable.
Safety monitoring is critical: nephrotoxicity and neurotoxicity are real risks, but manageable with appropriate protocols.
It's a reserve agent: should be used only when susceptibility data confirms need and alternatives have been exhausted.
Resistance is an emerging threat: judicious use is essential to preserve its utility.

Colistin: The Complete Guide to This Last-Resort Antibiotic